Evidence map›Paper›PMID 38558372›Full record

ArticleEndocrine2024

Effective TRIAC treatment of a THRβ-mutated patient with thyroid hormone resistance.

A Carbone, A Verrienti, D S Cito, M Sponziello, V Pecce, R Bruno

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Endocrine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

A CarboneEndocrine Unit- Asm Matera, Rome, Italy.
A VerrientiDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy.
D S CitoEndocrine Unit- Asm Matera, Rome, Italy.
M SponzielloDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy.
V PecceDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy.
R BrunoEndocrine Unit- Asm Matera, Rome, Italy. roccobruno1@virgilio.it.
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to thyroid hormone (RTH) is a rare autosomal dominant disease characterized by an alteration of thyroid hormone negative feedback, usually as a consequence of a mutation in the thyroid hormone receptor-b gene (THRβ). It is characterized by high variability of clinical manifestations, ranging from isolated abnormal thyroid function tests without symptoms to severe and impaired clinical conditions. Here we report the case of a woman who was diagnosed with RTHβ when she was 35 years old and was treated with 3,5,3-triiodiothyroacetic acid (TRIAC) because of the onset of clinical symptoms of hyperthyroidism. This therapy has been effective in controlling thyrotoxicosis for 5 years. After this time the patient developed an autoimmune hyperthyroidism, with TSH receptor autoantibodies appearance, which caused a loss of efficacy of the drug in controlling the disease. The development of different pathophysiological mechanisms of thyrotoxicosis, as in this case, could be the reason for both variability of disease manifestations and of loss of response to drug therapy.

Indexed as

Thyroid Hormone Receptors betaThyroid Hormone Resistance SyndromeAdultFemaleHumansMutationThyrotoxicosisTreatment OutcomeTriiodothyronine3,3',5-triiodothyroacetic acidThyroid Hormone Receptors betaTriiodothyronineGraves’ diseaseHyperthyroidismTHRβ

Identifiers

PMID38558372
OpenAlexW4393392650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.